A consortium to invest $80m in CytoReason.

A consortium, including OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific, agreed to invest $80m in CytoReason, a company developing computational disease models for predictive insights. “CytoReason is grateful for this infusion of new capital from industry technology powerhouses such as NVIDIA, Pfizer, and Thermo Fisher. The world understands that data alone is not enough, and that the future of data-driven insights is in data modeling. CytoReason is at the forefront of this revolution in pharma R&D,” David Harel, CytoReason Co-founder and CEO.